2023
Mortality and Severe Complications Among Newly Graduated Surgeons in the United States
Howard R, Thelen A, Chen X, Gates R, Krumm A, Millis M, Gupta T, Brown C, Bandeh-Ahmadi H, Wnuk G, Yee C, Ryan A, Mukherjee B, Dimick J, George B. Mortality and Severe Complications Among Newly Graduated Surgeons in the United States. Annals Of Surgery 2023, 279: 555-560. PMID: 37830271, PMCID: PMC10939969, DOI: 10.1097/sla.0000000000006128.Peer-Reviewed Original ResearchConceptsYears of practiceSevere complicationsRelative riskGeneral surgeonsIndependent practiceYears of independent practiceCareer surgeonsRelative risk of mortalityAmerican Board of SurgerySurgeon yearsMixed modelsSurgeon characteristicsRate of mortalityMedicare claimsComplicationsSurgeonsPatient outcomesPatientsMortalityAmerican BoardOutcomesEvaluating Educational Outcomes Using Patient Outcomes of New Surgeons Performing Partial Colectomy Compared to Cholecystectomy
George B, Thelen A, Howard R, Kendrick D, Chen X, Clark M, Gupta T, Brown C, Bandeh-Ahmadi H, Luckoski J, Wnuk G, Fan Z, Krumm A, Ryan A, Buyske J, Mukherjee B, Dimick J. Evaluating Educational Outcomes Using Patient Outcomes of New Surgeons Performing Partial Colectomy Compared to Cholecystectomy. Academic Medicine 2023, 98: s143-s148. PMID: 37983406, DOI: 10.1097/acm.0000000000005368.Peer-Reviewed Original ResearchConceptsPartial colectomyPatient outcomesYears of practiceExperienced surgeonSurgeon yearsRisk-adjusted ratesCholecystectomyColectomyTraining of surgeonsInpatient cholecystectomyComplicationsImprove surgical educationPatientsEvaluate educational outcomesSurgeonsSurgical residentsBenefit patientsInpatient operationsResidency trainingStudy periodDeathOutcomesSurgical educationMixed modelsTraining
2020
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database
Abraham H, Xia Y, Mukherjee B, Merajver S. Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. Breast Cancer Research And Treatment 2020, 185: 229-238. PMID: 33033965, DOI: 10.1007/s10549-020-05938-2.Peer-Reviewed Original ResearchConceptsSurvival timeBlack patientsBreast cancerWhite patientsSurvival rateIncidence rateIncidence of IBCInflammatory breast cancerPurposeInflammatory breast cancerResultsThe overall incidenceAge-adjusted incidence ratesMean survival timeRelative survival ratesIBC patientsT stageAggressive variantSkin progressionNo significant differenceDisease criteriaSurvival disparitiesPatientsSignificant differenceSurvivalConfidence intervalsMonths
2019
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Caram M, Ross R, Lin P, Mukherjee B. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. JAMA Network Open 2019, 2: e192589. PMID: 31002323, PMCID: PMC6481456, DOI: 10.1001/jamanetworkopen.2019.2589.Peer-Reviewed Original ResearchConceptsMinimally symptomatic metastatic castration-resistant prostate cancerSipuleucel-TProstate cancerSymptomatic metastatic castration-resistant prostate cancerDatabase of commercially insured patientsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerAge of patientsRetrospective cohort studyFactors associated with useAssociated with patientsCommercially insured patientsPatterns of treatmentConcurrent therapyTreated patientsCohort studyMultivariate analysisCancer therapyTherapyPatientsPhysician factorsCancerBarriers to treatmentBinomial logistic regressionLogistic regression